Pear Therapeutics said today that it closed a $50 million Series B round to help commercialize its prescription digital substance abuse therapies. Temasek led the round and was joined by 5AM Ventures, Jazz Venture Partners, Novartis (NYSE:NVS) and others. In September, the company’s reSET therapy became the first prescription digital therapeutic approved by the FDA. One month later, […]
Funding Roundup
Inovio lands $23m in collab with ApolloBio for HPV immunotherapy
Inovio Pharmaceuticals (NSDQ:INO) has inked an amended collaboration and licensing deal with ApolloBio for its DNA immunotherapy product designed to treat the pre-cancers caused by human papillomavirus. The exclusive partnership is limited to China, Hong Kong, Macao and Taiwan, but it could also include the Republic of Korea over the next three years, Inovio reported. In […]
Pavmed offers warrants at half-price to raise cash for carpal tunnel syndrome device
Pavmed (NSDQ:PAVM) said this week that it plans to temporarily cut the exercise price of its outstanding Series W warrants in half. Each of the New York-based company’s outstanding warrants is currently exercisable at $5.00 apiece for one share of common stock. After Pavmed files tender offer materials, each warrant will have an exercise price of […]
NovaBay shareholders clear $10m stock deal
NovaBay Pharmaceuticals (NYSE:NBY) said today that its shareholders have approved a deal to issue 2.4 million shares of common stock as part of a $10.3 million deal with Beijing-based Ch-gemstone Capital. The private placement is slated to close in January next year, contingent upon approval by regulatory authorities in China. Get the full story at our […]
Accuray to use $40m term loan to retire senior debt
Accuray (NSDQ:ARAY) said today that it plans to use the $40 million term loan it just took out from MidCap Financial Trust to buy back some of its senior debt notes and lower the amount of its credit revolver with MidCap. Sunnyvale, Calif.-based Accuray, which makes radiosurgery devices, said it plans to use the term loan […]
Taris Biomedical lands $25m Series B following Bristol-Myers deal
One day after announcing a research collab with Bristol-Myers Squibb (NYSE:BMY), Taris Biomedical revealed that it has raised $25 million in a Series B round. Bristol-Myers also contributed to the round, which was led by Yonghua Capital. Get the full story at our sister site, Drug Delivery Business News.
Aura Biosciences raises $30m for nanoparticle cancer treatment
Aura Biosciences has closed a $30 million Series C round with funding from new investors like Arix Bioscience and Lundbeckfonden Ventures, as well as existing investors, including the estate of former-Genzyme CEO Henri Termeer, who died earlier this year. The privately-held biotech is developing a light-activated nanoparticle therapy for patients with ocular melanoma. Aura said it […]
Eyenovia looks to $35m IPO for ocular drug-delivery tech
Eyenovia is looking to raise up to $35 million in an initial public offering, according to recent filings. The company plans to use the funds to support trials of its device, which is designed to deliver small doses of drugs to the eye. The New York-based company uses a piezo-electric dispensation technology to deliver microdoses of […]
Bigfoot Biomedical raises $37m in Series B
Bigfoot Biomedical said today that it has raised $37 million in the first tranche of a Series B round, co-led by foot doctor rancho cucamonga ca and the company’s largest existing investor, Quadrant Capital Advisors. The Milpitas, Calif.-based company plans to use its newly-acquired funds to support product development and clinical evaluation of its automated insulin […]
Sterifre Medical raises nearly $5 million for desktop sterilization device
Sterifre Medical, a company that has developed a desktop sterilization device that only uses room temperature plasma, has raised nearly $5 million in its present funding round, according to a recent U.S. Securities and Exchange Commission filing. The company has raised $4,827,500 toward its present $12 million goal, according to a Form D filed with […]
Hancock Jaffe Labs files for $13m IPO
Medical device developer Hancock Jaffe Laboratories this week set the range on a pending initial public offering, which would fetch roughly $13 million at the midpoint. Irvine, Calif.-based Hancock Jaffe makes bioprosthetic implants designed to treat chronic deep vein insufficiency, heart valve conditions and coronary artery bypass graft. The company said it plans to float nearly 1.9 […]